Japan is set to purchase 150 million doses of Novavax vaccine with the drug firm Takeda gave the duty of producing the formula for distribution that is to commence in the early parts of the following year.
There has been no specific mention of how much this purchase cost but it has been affirmed that Takeda will dominate the sector of trying out the vaccines in local clinics.
Japan has approved other vaccines like Moderna, Pfizer and AstraZeneca even though the distribution of AstraZeneca is done in a much limited way.
The Novavax vaccine is said to have an edge over other vaccines because it does not have to be kept at an extremely low temperature.
Novavax is reported to be a double jab vaccine that will be seen to using proteins in the body to lift pieces of the covid infection, and making them harmless to create some immune response.
The US firm producing Novavax stated that the vaccine stands a 90% chance against the virus while the United States and the European Union are yet to convey their review of the vaccine’s potency.
READ ALSO: Japan’s Economy Grows Amidst Pandemic Influx
The European Commission in the previous month mentioned that a preparatory deal had been signed to ensure that about 200 million doses of the Novavax vaccines are delivered; which is enough signals that the European Union drug regulator approves the vaccines.
Japan vaccine distribution since the pandemic has been reported to have started late and slow but has been picking up pace recent with almost half of the population having received full vaccination.